CC Diagnostics is a company dedicated to advancing cervical cancer detection through innovative medical technologies. Their primary product, the Methica CC Kit, utilizes PCR-based epigenetic DNA analysis to identify cervical cancer at its earliest stages. This approach has demonstrated a 97% detection rate, surpassing traditional Pap smear tests by 21% in sensitivity.
In a recent clinical validation study using samples from the Dutch National Screening Program, the Methica CC Kit achieved 97% sensitivity in cancer detection without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and marks a significant advancement in cervical cancer diagnostics.
CC Diagnostics is headquartered in Groningen, Netherlands, and collaborates with various partners, including the University Medical Centre Groningen (UMCG) and IQ Products. Their mission is to empower women by providing optimal cervical cancer screening that is accurate, accessible, and comfortable.
